Eldigit

Eldigit Uses, Dosage, Side Effects, Food Interaction and all others data.

Eldigit is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold.

Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.

Eldigit
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Eldigit
Availability	Discontinued
Generic	Pipecuronium
Pipecuronium Other Names	Pipecurium, Pipecuronium
Type	Tablet
Formula	C₃₅H₆₂N₄O₄
Weight	Average: 602.8912 Monoisotopic: 602.477106492
Groups	Approved
Therapeutic Class	Non depolarizing muscle relaxants
Manufacturer
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Used as a muscle relaxant during anesthesia and surgical procedures.

How Eldigit works

Dosage

Eldigit dosage

Intravenous (Adult)-

Initial dose: 80-100 mcg/kg.
Subsequent doses: 10-20 mcg/kg.
Initial dose following suxamethonium admin or in patients at high risk: 50-60 mcg/kg.
Initial dose for caesarean section: 35 mcg/kg.

Side Effects

Transient hypotension, bradycardia, reduced cardiac output.

Precaution

Pulmonary disease, respiratory insufficiency, asthma, neuromuscular disease, dehydration, severely ill patients, hepatic or renal impairment. Doses in obese patients should be based on patient's ideal body weight. Pregnancy, lactation.

Interaction

Actions antagonised by cholinesterases and long term carbamazepine, phenytoin or corticosteroids usage. Enhanced block when used with drugs that have neuromuscular blocking activity such as lidocaine, quinidine, verapamil and aminoglycosides.

Eldigit Drug Interaction

Unknown: aspirin, epinephrine, Allergy , glipizide, glycerin, sodium iodide, arginine, acetaminophen, procaine penicillin, valproic acid, thiamine, cyanocobalamin, riboflavin, pyridoxine, ascorbic acid, ergocalciferol, cholecalciferol, phytonadione, phytonadione, zinc sulfate

Eldigit Disease Interaction

Major: liver disease, paresis, pulmonary impairModerate: obesity, renal dysfunction

Half Life

Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]

Pregnancy & Breastfeeding use

Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.